← Back to Clinical Trials
Recruiting NCT04608357

NCT04608357 Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04608357
Status Recruiting
Phase
Sponsor Sunnybrook Health Sciences Centre
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 25 participants
Start Date 2021-07-21
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Needle Core Biopsies

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 25 participants in total. It began in 2021-07-21 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators propose to use clinically validated patient avatar technology ("PDXovo") that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.

Eligibility Criteria

Inclusion Criteria: 1. Age 18+. 2. Metastatic breast cancer irrespective of subtype. 3. Measurable disease as per RECIST 1.1 criteria. 4. Metastatic disease involving the lymph nodes and/or visceral organs is required. 5. Willingness to undergo a biopsy prior to the start of planned systemic therapy. Exclusion Criteria: 1. Lack of feasibility to obtain a core biopsy of a metastatic site other than the bone (e.g. a metastatic lesion cannot be safely sampled due to proximity to vasculature). 2. Inability to provide informed consent.

Contact & Investigator

Central Contact

Katarzyna J Jerzak, MD MSc FRCPC

✉ katarzyna.jerzak@sunnybrook.ca

📞 416-480-6100

Principal Investigator

Katarzyna J Jerzak, MD MSc FRCPC

PRINCIPAL INVESTIGATOR

Sunnybrook Health Sciences Centre

Frequently Asked Questions

Who can join the NCT04608357 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04608357 currently recruiting?

Yes, NCT04608357 is actively recruiting participants. Contact the research team at katarzyna.jerzak@sunnybrook.ca for enrollment information.

Where is the NCT04608357 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT04608357 clinical trial?

NCT04608357 is sponsored by Sunnybrook Health Sciences Centre. The principal investigator is Katarzyna J Jerzak, MD MSc FRCPC at Sunnybrook Health Sciences Centre. The trial plans to enroll 25 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology